What are the odds we get an heir to Paxlovid?

Off artificial intelligence, Biotech, biotechnology, Business, drug development, drug prices, drug pricing, FDA, finance, genetics, government agencies, Health, Human Health, Life Sciences, Medicine, Pharma, Pharmaceuticals, Politics, Science and Research, The Readout

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Morning! Today, we look at some promising, but early, gene therapy data from Lexeo Therapeutics, examine Medicare’s new price negotiation rules and their impact on innovation, and more.

Read the rest…

Read Original Article: What are the odds we get an heir to Paxlovid? »

About The Author